1 min read
Add as a preferred source on GoogleRoivant Highlights IMVT-1402 for 85,000 Difficult-to-Treat RA Patients
Roivant estimates 85,000 people have difficult-to-treat RA. At Week 28, 92.5% of the 600-milligram group maintained an ACR20 response, compared with about 75% on placebo.
Roivant highlighted IMVT-1402 and an estimated 85,000 difficult-to-treat rheumatoid arthritis patients in its Investor Day outline.
At Week 28, 92.5% of patients in the 600-milligram group maintained an ACR20 response, compared with about 75% of patients on placebo. The 300-milligram group did not preserve the response.
Roivant’s ongoing discussions with the Food and Drug Administration (FDA) cover trial design, endpoints and the number of Phase III studies.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.